AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3443597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranayamic breathing exercises using a Pink City lung exerciser alone
Number of subjects: 12
Study 3443597 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercises using the lung exerciser with hot, humid air
Number of subjects: 12
Study 3443597 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo administration)
Number of subjects: 12
Study 31674093 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioengineered bilayered living cell construct (BLCC) plus compression therapy
Number of subjects: 30
Study 31674093 — intervention group
Group type: COMPARATOR
Intervention: Compression therapy (control)
Number of subjects: 30
Study 31674093 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioengineered bilayered living cell construct (BLCC)
Number of subjects: 30
Study 28574780 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions targeting treatment engagement in youth mental health services
Number of subjects: 50
Study 28574780 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific practices distilled from effective interventions
Number of subjects: 50
Study 27192358 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sanitation coverage (27 percentage points)
Number of subjects: 301
Study 27192358 — intervention group
Group type: COMPARATOR
Intervention: Community drinking water sources with detected pathogens
Number of subjects: 301
Study 27192358 — intervention group
Group type: COMPARATOR
Intervention: Higher levels of human and animal fecal marker detection in homes
Number of subjects: 301
Study 27192358 — intervention group
Group type: COMPARATOR
Intervention: Tubewells
Number of subjects: 301
Study 27192358 — intervention group
Group type: COMPARATOR
Intervention: Ponds
Number of subjects: 301
Study 26215589 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive program with motivational interviewing (MI) sessions by trained occupational physicians, 4 face-to-face and 3 by telephone, and more choices of health promotion activities in the HRA.
Number of subjects: 0
Study 26215589 — intervention group
Group type: COMPARATOR
Intervention: Limited health program (control) consisting of an HRA as a decision aid for lifestyle changes and a newsletter every 3 months.
Number of subjects: 0
Study 23306144 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years (IY) parenting program
Number of subjects: 481
Study 23306144 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 481
Study 20613471 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 0 (radiofrequency denervation based solely on clinical findings)
Number of subjects: 151
Study 20613471 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (denervation contingent on a positive response to a single diagnostic block)
Number of subjects: 151
Study 20613471 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (denervation only if positive response to comparative blocks with lidocaine and bupivacaine)
Number of subjects: 151
Study 20613471 — intervention group
Group type: COMPARATOR
Intervention: Group 0
Number of subjects: 151
Study 20613471 — intervention group
Group type: COMPARATOR
Intervention: Group 1
Number of subjects: 151
Study 20613471 — intervention group
Group type: COMPARATOR
Intervention: Group 2
Number of subjects: 151
Study 18568441 — intervention group
Group type: EXPERIMENTAL
Intervention: Femal (160 mg twice-daily for four menstrual cycles)
Number of subjects: 50
Study 18568441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 16616126 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete group (360 degrees of axial walls)
Number of subjects: 50
Study 16616126 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatal group (180 degrees of axial walls)
Number of subjects: 50
Study 16616126 — intervention group
Group type: EXPERIMENTAL
Intervention: Labial group (180 degrees of axial walls)
Number of subjects: 50
Study 16616126 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal group (180 degrees of axial walls)
Number of subjects: 50
Study 16616126 — intervention group
Group type: COMPARATOR
Intervention: Level group (no retained coronal tooth structure)
Number of subjects: 50
Study 12789181 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with Metvix and 75 J/cm² red light, performed twice weekly for 12 weeks, then once weekly.
Number of subjects: 10
Study 12789181 — intervention group
Group type: COMPARATOR
Intervention: Paromomycin sulfate, administered once daily.
Number of subjects: 10
Study 10619534 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention with counseling to adopt a diet containing 28% or less of calories from total fat, <8% saturated fat, up to 9% polyunsaturated fat, and 11% monounsaturated fat, and dietary cholesterol intake of less than 75 mg/1,000 kcal
Number of subjects: 663
Study 10619534 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group (control)
Number of subjects: 663
Study 7646090 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (20 ppm x 10 minutes)
Number of subjects: 13
Study 7646090 — intervention group
Group type: COMPARATOR
Intervention: Intravenous prostacyclin (20 ng.kg‐1.min‐1 x 10 minutes)
Number of subjects: 13
Study 7646090 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 13
Study 7646090 — intervention group
Group type: COMPARATOR
Intervention: Intravenous prostacyclin
Number of subjects: 13
Study 2520394 — intervention group
Group type: EXPERIMENTAL
Intervention: Codetron (Group A)
Number of subjects: 0
Study 2520394 — intervention group
Group type: COMPARATOR
Intervention: Sham Codetron (Group B)
Number of subjects: 0
Study 616209 — intervention group
Group type: EXPERIMENTAL
Intervention: Jodamid
Number of subjects: 215
Study 616209 — intervention group
Group type: COMPARATOR
Intervention: Metrizoic acid
Number of subjects: 215
Study 31183585 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling (1-3 sessions) and group counseling (6 sessions per week for 6 weeks)
Number of subjects: 80
Study 31183585 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 80
Study 28377389 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus suspension administered orally
Number of subjects: 20
Study 28377389 — intervention group
Group type: COMPARATOR
Intervention: Prolonged-release tacrolimus suspension administered via nasogastric tube
Number of subjects: 20
Study 28377389 — intervention group
Group type: COMPARATOR
Intervention: Intact capsules
Number of subjects: 20
Study 25205761 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-the-shelf, extra-depth footwear
Number of subjects: 120
Study 23955148 — intervention group
Group type: EXPERIMENTAL
Intervention: NVS123 formulated as dry filled capsules administered orally with high-fat meal
Number of subjects: 0
Study 23955148 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative formulations developed and assessed in preclinical and/or clinical studies
Number of subjects: 0
Study 23955148 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorphous formulation of NVS123
Number of subjects: 0
Study 23955148 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroplus population simulations
Number of subjects: 0
Study 21563916 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy (131I) with an administered activity of 1.85-4.07 MBq per gram of thyroid tissue (average 261 ± 162 MBq) in Group 3
Number of subjects: 600
Study 21563916 — intervention group
Group type: COMPARATOR
Intervention: Radioiodine therapy (131I) with varying activities in other groups
Number of subjects: 600
Study 19686420 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (1 mg intravenous)
Number of subjects: 28
Study 19686420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 16303780 — intervention group
Group type: EXPERIMENTAL
Intervention: HFR (Haemodiafiltration with online regeneration of ultrafiltrate)
Number of subjects: 25
Study 16303780 — intervention group
Group type: EXPERIMENTAL
Intervention: Online HDF (Haemodiafiltration)
Number of subjects: 25
Study 16303780 — intervention group
Group type: COMPARATOR
Intervention: Wash-out period with HD (standard bicarbonate dialysis)
Number of subjects: 25
Study 15504192 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.4 mg kg(‐1)
Number of subjects: 161
Study 15504192 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 1 mg kg(‐1)
Number of subjects: 161
Study 15504192 — intervention group
Group type: COMPARATOR
Intervention: Control (no relaxant)
Number of subjects: 161
Study 10795733 — intervention group
Group type: EXPERIMENTAL
Intervention: Equation development sample (n = 50)
Number of subjects: 75
Study 10795733 — intervention group
Group type: EXPERIMENTAL
Intervention: Equation validation sample (n = 25)
Number of subjects: 75
Study 9061310 — intervention group
Group type: EXPERIMENTAL
Intervention: Unheated cornstarch (106 g of CHO)
Number of subjects: 10
Study 9061310 — intervention group
Group type: COMPARATOR
Intervention: Mixed equicaloric meal (58 g of CHO)
Number of subjects: 10
Study 9061310 — intervention group
Group type: COMPARATOR
Intervention: Smaller mixed meal (17 g of CHO)
Number of subjects: 10
Study 7930243 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency balloon angioplasty
Number of subjects: 31
Study 7930243 — intervention group
Group type: COMPARATOR
Intervention: Other procedures as rescue
Number of subjects: 31
Study 2467137 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg once daily added to captopril 25 mg twice daily for 4 weeks
Number of subjects: 0
Study 2467137 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to captopril 25 mg twice daily for 4 weeks
Number of subjects: 0
Study 29775170 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg twice daily
Number of subjects: 120
Study 29775170 — intervention group
Group type: COMPARATOR
Intervention: Dose-adjusted warfarin (INR 2-3)
Number of subjects: 120
Study 28148474 — intervention group
Group type: EXPERIMENTAL
Intervention: BPMED intervention (text messaging support)
Number of subjects: 123
Study 26775454 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-visit vaccination video education
Number of subjects: 105
Study 26775454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video education)
Number of subjects: 105
Study 23680036 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPS (multi-ingredient performance supplement)
Number of subjects: 24
Study 23680036 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isocaloric maltodextrin)
Number of subjects: 24
Study 21252092 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 132
Study 21252092 — intervention group
Group type: COMPARATOR
Intervention: Allo-HSCT
Number of subjects: 132
Study 18433709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pink grapefruit juice
Number of subjects: 32
Study 18433709 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 32
Study 18433709 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 32
Study 18433709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 16271817 — intervention group
Group type: EXPERIMENTAL
Intervention: Event related brain potential (ERP) recordings during global-local reaction time task
Number of subjects: 30
Study 16271817 — intervention group
Group type: EXPERIMENTAL
Intervention: P100 responses
Number of subjects: 30
Study 16271817 — intervention group
Group type: EXPERIMENTAL
Intervention: N150 responses
Number of subjects: 30
Study 16271817 — intervention group
Group type: EXPERIMENTAL
Intervention: P300 responses
Number of subjects: 30
Study 15272967 — intervention group
Group type: EXPERIMENTAL
Intervention: Justice attitude (person factor) and responsibility for damage (situation factor)
Number of subjects: 80
Study 15272967 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing negativity of attitude toward equality
Number of subjects: 80
Study 11202339 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular testing in children with migraine
Number of subjects: 20
Study 11202339 — intervention group
Group type: COMPARATOR
Intervention: Control group of 15 healthy children
Number of subjects: 20
Study 8971437 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide (900 mg day-1)
Number of subjects: 438
Study 8971437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study 1462531 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 16000
Study 1462531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16000
Study 6337405 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of guanabenz twice daily as well as hydrochlorothiazide
Number of subjects: 25
Study 6337405 — intervention group
Group type: COMPARATOR
Intervention: Placebo and hydrochlorothiazide
Number of subjects: 25
Study 6337405 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of guanabenz and hydrochlorothiazide vs placebo and hydrochlorothiazide
Number of subjects: 25
Study 31360445 — intervention group
Group type: EXPERIMENTAL
Intervention: WASH intervention (water supply, sanitation facilities, handwashing facilities, drinking water filters, behavior change education)
Number of subjects: 100
Study 31360445 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison schools received the intervention after research activities ended)
Number of subjects: 100
Study 30286797 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education programme with text-message support over 12 months
Number of subjects: 290
Study 30286797 — intervention group
Group type: COMPARATOR
Intervention: Standard care and a physical activity information leaflet
Number of subjects: 290
Study 30286797 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based structured education sessions
Number of subjects: 290
Study 30286797 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-message support
Number of subjects: 290
Study 30286797 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes at 12 months
Number of subjects: 290
Study 27195735 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimalist shoes training for 6 months
Number of subjects: 38
Study 27195735 — intervention group
Group type: COMPARATOR
Intervention: Standard shoes training for 6 months (Control)
Number of subjects: 38
Study 24648302 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioavailability-boosted curcuminoids preparation (180 mg/day)
Number of subjects: 80
Study 24648302 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 80
Study 21786525 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ketoprofen administered intravenously one hour before the procedure and at 8, 24, 36 and 48 h after
Number of subjects: 52
Study 21786525 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline) administered intravenously one hour before the procedure and at 8, 24, 36 and 48 h after
Number of subjects: 52
Study 21786525 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ketoprofen and placebo)
Number of subjects: 52
Study 19660897 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise rehabilitation
Number of subjects: 217
Study 19660897 — intervention group
Group type: COMPARATOR
Intervention: Invasive revascularization with stents
Number of subjects: 217
Study 16735487 — intervention group
Group type: EXPERIMENTAL
Intervention: +MTZ
Number of subjects: 75
Study 16735487 — intervention group
Group type: COMPARATOR
Intervention: ‐MTZ
Number of subjects: 75
Study 15538130 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 31
Study 11999818 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide infusion for 48 hours
Number of subjects: 43
Study 11999818 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide infusion for 48 hours plus 72 hours subcutaneous injection
Number of subjects: 43
Study 11999818 — intervention group
Group type: COMPARATOR
Intervention: Octreotide infusion
Number of subjects: 43
Study 11999818 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of octreotide for another 72 hours
Number of subjects: 43
Study 9052320 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 150
Study 9052320 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg
Number of subjects: 150
Study 9052320 — intervention group
Group type: COMPARATOR
Intervention: 0.9% Saline (Placebo)
Number of subjects: 150
Study 7871060 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 22
Study 7871060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 3540813 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS treatment
Number of subjects: 18
Study 3540813 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS treatment
Number of subjects: 18
Study 1124809 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide‐imipramine
Number of subjects: 0
Study 1124809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31331564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine plus quince syrup
Number of subjects: 96
Study 31331564 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 96
Study 28371141 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV)
Number of subjects: 100
Study 28371141 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy for HFrEF alone
Number of subjects: 100
Study 24383121 — intervention group
Group type: EXPERIMENTAL
Intervention: HM-ON (Home Monitoring ON)
Number of subjects: 151
Study 24383121 — intervention group
Group type: COMPARATOR
Intervention: HM-OFF (Home Monitoring OFF)
Number of subjects: 151
Study 22384549 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantization diagnostic standard for IgA nephropathy of QYDS
Number of subjects: 1016
Study 19375592 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg daily for 6 months
Number of subjects: 24
Study 19375592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17276018 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate on-site vaccination availability
Number of subjects: 3181
Study 17276018 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentives
Number of subjects: 3181
Study 17276018 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination willingness
Number of subjects: 3181
Study 17276018 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination uptake by site
Number of subjects: 3181
Study 17276018 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HAV and anti-HBc seroprevalence
Number of subjects: 3181
Study 15611220 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention program (six modules in five weekly group sessions)
Number of subjects: 22
Study 15611220 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no specific intervention mentioned)
Number of subjects: 22
Study 11275669 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride and baking soda (F+NaHCO(3)) dentifrice
Number of subjects: 0
Study 11275669 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride (F) dentifrice
Number of subjects: 0
Study 11275669 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 0
Study 9011700 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete metastasectomy
Number of subjects: 5206
Study 9011700 — intervention group
Group type: COMPARATOR
Intervention: Incomplete metastasectomy
Number of subjects: 5206
Study 9011700 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete metastasectomy with disease-free interval of 0 to 11 months
Number of subjects: 5206
Study 9011700 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete metastasectomy with disease-free interval of more than 36 months
Number of subjects: 5206
Study 9011700 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete metastasectomy with single lesions
Number of subjects: 5206
Study 9011700 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete metastasectomy with four or more lesions
Number of subjects: 5206
Study 9011700 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete metastasectomy with germ cell tumors
Number of subjects: 5206
Study 9011700 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete metastasectomy with disease-free intervals of 36 months or more
Number of subjects: 5206
Study 9011700 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete metastasectomy with single metastases
Number of subjects: 5206
Study 8275659 — intervention group
Group type: EXPERIMENTAL
Intervention: TUDCA (Tauro-ursodeoxycholic acid)
Number of subjects: 34
Study 8275659 — intervention group
Group type: COMPARATOR
Intervention: UDCA (Ursodeoxycholic acid)
Number of subjects: 34
Study 3430263 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (B)
Number of subjects: 50
Study 3430263 — intervention group
Group type: COMPARATOR
Intervention: Mineral oil therapy (M)
Number of subjects: 50
Study 29843895 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior plating and anterior fixation with percutaneous anterior column screw (double column group)
Number of subjects: 30
Study 29843895 — intervention group
Group type: COMPARATOR
Intervention: Posterior fixation alone (single column group)
Number of subjects: 30
Study 26585287 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2940094 (40 mg once daily for 8 weeks)
Number of subjects: 0
Study 26585287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24742217 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based peer support (mother-to-mother) provided by trained peer volunteers.
Number of subjects: 0
Study 24742217 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned in the abstract.
Number of subjects: 0
Study 23767831 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0
Study 23767831 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (administered every 2 weeks)
Number of subjects: 0
Study 20684981 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft aortic root replacement (Ross procedure)
Number of subjects: 216
Study 20684981 — intervention group
Group type: COMPARATOR
Intervention: Homograft aortic root replacement
Number of subjects: 216